Latest News
-
Monday - February 12, 2018
Not intended for U.S. and UK Media
New data for aflibercept show prolonged injection intervals
Data from ALTAIR study demonstrate injection appointments at an interval of 12 weeks or more / New data submitted to EMA to update the current product information » more
-
Wednesday - February 7, 2018
Not intended for U.S. and UK Media: 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium:
Bayer to showcase latest prostate cancer research at ASCO GU 2018 Cancer Symposium
New data on the long-term efficacy and safety of Xofigo® (radium-223 dichloride) / Update on ongoing studies with darolutamide, a novel investigational oral androgen receptor (AR) antagonist, including the ARASENS pivotal trial in men with metastatic hormone-sensitive prostate cancer (mHSPC) » more
-
Wednesday - February 7, 2018
Agreements will be signed at Fruit Logistica:
Bayer and NGOs collaborate to support smallholder farmers
Farmers will benefit from expertise, technologies, and better access to markets / Solidaridad supports smallholder farmers to produce food sustainably / Triptolemos Foundation commissions UNESCO Chair to innovate global food system » more
-
Tuesday - January 23, 2018
Higher crop yields via mobile phone:
Bayer supports innovative myAgro start-up with funding of more than USD 600,000 to assist smallholder farmers in West Africa
Small amounts of money are saved by farmers via mobile phones in the form of myAgro scratch cards and exchanged for high-quality seed and fertilizer / Bayer’s donation will help expand this social innovation to other regions of Africa and and support an initiative to combat infections » more
-
Wednesday - January 17, 2018
Not intended for U.S. and UK Media - 2018 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancer Symposium:
Bayer to highlight new research at ASCO GI 2018 Cancer Symposium
Data continue to affirm the impact of Stivarga® (regorafenib) and Nexavar® (sorafenib) / New analyses from ongoing trials for the treatment of metastatic colorectal cancer (mCRC) and hepatocellular carcinoma (HCC) » more
-
Tuesday - January 16, 2018
Not intended for U.S. or UK Media
FDA report reaffirms safety profile and effectiveness of Bayer’s Xarelto® in routine clinical practice » more
-
Thursday - January 11, 2018
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer sells 10.4 percent stake in Covestro
Placement volume considerably higher than planned » more
-
Wednesday - January 10, 2018
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer further reduces holding in Covestro
Accelerated bookbuilding process started » more
-
Wednesday - January 10, 2018
Support for certification of soy in Brazil:
Bayer and Round Table on Responsible Soy renew cooperation » more
-
Monday - January 8, 2018
Commitment to North Rhine-Westphalia research site:
Bayer inaugurates new greenhouse for insecticide research
Company aims to consolidate leading position in insecticides market / Investment of around EUR 45 million in new building complex / Facility improves ability to develop new selective insecticides / 11,000 m2 greenhouse space plus laboratories and offices / Greenhouse offers room for 60 employees » more
-
Wednesday - December 20, 2017
Not intended for U.S. and UK Media
Bayer announces initiation of rolling submission of new drug application in the U.S. for larotrectinib for the treatment of TRK fusion cancers
Completion of NDA submission expected in early 2018 » more
-
Wednesday - December 13, 2017
Not intended for U.S. and UK Media
Bayer receives approval in China for Stivarga® (regorafenib) for the second-line systemic treatment of liver cancer
Approval based on data from the Phase III RESORCE study where Stivarga® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) » more
-
Monday - December 11, 2017
Not intended for U.S. and UK Media
Bayer’s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease
The rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack / The application for marketing approval is based on the COMPASS study » more
-
Thursday - December 7, 2017
Not intended for U.S. and UK Media - American Society of Hematology (ASH) 59th Annual Meeting & Exposition:
Thirteen abstracts highlighting data from Bayer’s rivaroxaban will be presented at ASH 2017, two addressing cancer-associated thrombosis
Results from Select-D trial demonstrate lower rates of venous thromboembolism (VTE) recurrence with rivaroxaban than with the current standard of care / The development of VTE in cancer patients is associated with high morbidity and mortality / Rivaroxaban abstracts covering both clinical and real-world studies in venous and arterial thromboembolism » more
-
Thursday - December 7, 2017
Bayer is taking a leadership role in driving transparency:
New Bayer transparency website launched
Enabling access to safety-relevant plant protection study summaries / Fostering an open and transparent dialog with society / Support to authorities in dealing with data requests » more
-
Thursday - December 7, 2017
Not intended for U.S. and UK Media
Bayer to highlight new oncology research at ASH 2017
New data include further safety and efficacy follow-up from the CHRONOS-1 study in indolent non-Hodgkin’s lymphoma » more
-
Monday - April 24, 2017
World Malaria Day 2017:
Bayer partners with Goodbye Malaria to help “End Malaria for Good” » more
-
Tuesday - December 13, 2016
Monsanto Shareowners Approve Merger with Bayer
Key Milestone in Merger to Create a Global Leader in Agriculture / Close of Transaction Expected by the End of 2017 » more
-
Monday - December 12, 2016
Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing
BlueRock Therapeutics is focused on breakthrough treatments based on latest stem cell technology in combination with superior cell differentiation protocols / BlueRock Therapeutics’ vision is to cure diseases with significant cell loss and diminished self-repair potential with an initial focus on cardiovascular, neurological and other conditions » more
-
Friday - August 19, 2016
Bayer and CRISPR Therapeutics joint venture, named Casebia Therapeutics, establishes operations in Cambridge, MA
Transaction formally closed in the first quarter of 2016 / Laboratory and office space will be near Kendall Square in Cambridge, MA / Hiring is underway and efforts have begun on initial programs in hematology and ophthalmology » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Download Center - Selection
Bayer TV